$CLNN

Clene Inc.

Clene develops clean-surfaced nanotechnology therapeutics for diseases, with a focus on central nervous system disorders including amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease. Its platform produces catalytically active nanocrystals and ionic solutions of transition elements. The lead drug candidate, CNM-Au8, is an oral gold-nanocrystal suspension being developed for those three disorders. Other early-stage assets include CNM-ZnAg, an aqueous zinc-and-silver ion solution, and CNM-AgZn17, a zinc-and-silver gel for topical use. Clene also develops low-concentration dietary supplements through its wholly owned subsidiary dOrbital and an exclusive license with 4Life Research. Products include dOrbital’s rMetx zinc-silver supplement and 4Life’s KHC46 gold supplement, which 4Life markets and distributes worldwide under the exclusive license. Clene is headquartered in Salt Lake City, Utah.

No enriched coverage for $CLNN in the last 7 days.

No SEC Form 4 filings for $CLNN in the last 30 days.

See all $CLNN insider activity →
Low

Clene Reports Q3 2026 Results, $3.9 Million Net Income

Clene reported Q3 2026 revenue of $56,000 and net income of $3.9 million, improving from a $8.8 million loss in the prior year. The company's operating loss was $6.3 million, with net income boosted by a $10.9 million favorable change in warrant and derivative liabilities. Clene submitted an NDA for accelerated approval of CNM-Au8 for ALS, with a Phase 3 trial planned for Q2 2027. The company has $9.9 million in cash and expects resources to last through mid-Q1 2027.

CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8 ® in amyotrophic lateral sclerosis (ALS

CLNN sentiment & insider activity

Recent CLNN coverage spans regulation, earnings and financial news.

What's driving CLNN

AlphAI scores every news story that mentions CLNN with an AI model for sentiment and relevance, and aggregates insider trades from Clene Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CLNN

Score

Clene Reports Q3 2026 Results, $3.9 Million Net Income

Clene reported Q3 2026 revenue of $56,000 and net income of $3.9 million, improving from a $8.8 million loss in the prior year. The company's operating loss was $6.3 million, with net income boosted by a $10.9 million favorable change in warrant and derivative liabilities. Clene submitted an NDA for accelerated approval of CNM-Au8 for ALS, with a Phase 3 trial planned for Q2 2027. The company has $9.9 million in cash and expects resources to last through mid-Q1 2027.

$CLNNHighEarnings

CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS

Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Third QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8 ® in amyotrophic lateral sclerosis (ALS

$CLNNLowContract· $7.2M

Clene Inc. (CLNN): Entry into a Material Definitive Agreement

Clene Inc. (CLNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Previously, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”) announced (i) on October 5, 2023, a four-year, $45.1 million grant (“the NIH

HC Wainwright & Co. reiterates Buy rating on Clene, $31 price target

HC Wainwright & Co. maintained a Buy rating on Clene's stock with a $31 price target, implying a 900% upside from the Oct 16 close. The firm cited promising clinical data for CNM-Au8, showing reductions in biomarkers linked to ALS progression, and a strategic regulatory milestone with the NDA submission and planned Phase 3 trial.

$CLNNHighAI 9/10Clinical / regulatory· NDA submission

CLENE ANNOUNCES NEW DRUG APPLICATION SUBMISSION TO FDA FOR CNM-Au8 FOR THE TREATMENT OF ALS

Clene Inc. (CLNN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CLENE ANNOUNCES NEW DRUG APPLICATION SUBMISSION TO FDA FOR CNM-Au8 FOR THE TREATMENT OF ALS ● NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, October 19, 2026 — Clene Inc. (N

Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision

Clene Inc (CLNN) plans to submit an FDA application for its ALS drug CNM-Au8 in Q4, aiming for a mid-2027 decision. CEO Etherington cited survival benefits and neurofilament light changes as supporting data. The company has held five FDA meetings and completed financing to support the filing. If approved, CNM-Au8 could address thousands of patients annually, with Clene working on insurer and payer agreements.

$CLNNMedOffering· $4M · priced

Clene Inc. (CLNN): Entry into a Material Definitive Agreement

Clene Inc. (CLNN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 CLENE ANNOUNCES $4 MILLION REGISTERED DIRECT OFFERING ● Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders ● $4 million registered dire

Related tickers